CRISPR Therapeutics CMO Phuong Khanh Morrow resigns effective Jan 26, 2024

CRISPR Therapeutics AG

Dr. Morrow stepped down as Chief Medical Officer on Dec 14, 2023, effective Jan 26, 2024.
Resignation is not due to any disagreement with the company.
No successor or interim CMO has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Phuong Khanh Morrow

Chief Medical Officer

CRSP · CRISPR Therapeutics AG

Effective: 2024-01-26
Filed: December 19, 2023, 6:59 PM ET

On December 14, 2023, Phuong Khanh Morrow, M.D., FACP resigned as Chief Medical Officer of CRISPR Therapeutics AG (the “Company”) to be effective as of January 26, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Phuong Khanh Morrow resigned as Chief Medical Officer at CRISPR Therapeutics AG.

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On December 14, 2023, Phuong Khanh Morrow, M.D., FACP resigned as Chief Medical Officer of CRISPR Therapeutics AG (the “Company”) to be effective as of January 26, 2024.

View on SEC.gov

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-23-071505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.